Stock ANTIBIOTICE SA
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Antibiotice SA Share Price Bucharest S.E.

Equities

Pharmaceuticals

End-of-day quote Bucharest S.E.
Other stock markets
- RON - Intraday chart for Antibiotice SA
28/02 Antibiotice S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Antibiotice S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI

Financials

Sales 2022 50Cr 11Cr 901.59Cr Sales 2023 62Cr 13Cr 1.12TCr Capitalization 94Cr 20Cr 1.7TCr
Net income 2022 3.8Cr 82.96L 69Cr Net income 2023 8.1Cr 1.77Cr 146.84Cr EV / Sales 2022 0.92 x
Net Debt 2022 7.93Cr 1.73Cr 143.68Cr Net Debt 2023 6.45Cr 1.41Cr 116.92Cr EV / Sales 2023 1.63 x
P/E ratio 2022
9.87 x
P/E ratio 2023
11.5 x
Employees -
Yield 2022
1.4%
Yield 2023
3.3%
Free-Float 17.57%
More Fundamentals * Assessed data

Latest news about Antibiotice SA

Antibiotice S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Antibiotice S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Antibiotice S.A. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Antibiotice S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Antibiotice S.A. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Antibiotice S.A. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Antibiotice S.A. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Antibiotice S.A. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Antibiotice S.A. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Antibiotice S.A. Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Antibiotice S.A. Reports Earnings Results for the Half Year Ended June 30, 2021 CI
Antibiotice S.A. Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
Antibiotice S.A. Reports Earnings Results for the Full Year Ended December 31, 2020 CI
Antibiotice S.A. Reports Earnings Results for the Nine Months Ended September 30, 2020 CI
Antibiotice S.A. Reports Earnings Results for the Half Year Ended June 30, 2020 CI
More news

Press releases Antibiotice SA

Antibiotice S A : Iasi invests in digitalization2024-04-25 PU
Antibiotice S A : Iasi invests in digitalization for the transition to a sustainable business PU
Antibiotice S A : The Antibiotice Iași business growth by 24% in 2023 strengthens the company’s development PU
Antibiotice S A : Iasi has commissioned a 2.5 MW photovoltaic plant, financed by the RRRP, which will provide over 25% of the electricity requirements PU
Antibiotice S A : Commissioning of the 2.5 MW Photovoltaic Power Plant2024-03-28 PU
More press releases

Managers and Directors - Antibiotice SA

Managers TitleAgeSince
Ioan Nani CEO
 Chief Executive Officer 64 01/87/01
Paula-Luminita Coman DFI
 Director of Finance/CFO 56 01/91/01
Cornelia Moraru CTO
 Chief Tech/Sci/R&D Officer 58 05/03/05
Members of the board TitleAgeSince
Ioan Nani CEO
 Chief Executive Officer 64 01/87/01
Mihai Trifu BRD
 Director/Board Member 41 26/21/26
Catalin-Codrut Popescu BRD
 Director/Board Member 48 26/21/26
More insiders

Company Profile

Antibiotice SA is a Romania-based company primarily active in the pharmaceutical industry. The Company manufactures drugs in five pharmaceutical forms: powder for injectable solutions and suspensions, capsules, tablets, suppositories and preparations. The Company's products are designed to treat a range of diseases, including infectious, dermatology, cardiovascular, digestive and musculoskeletal system related. The Company operates eight certified production lines. Its portfolio includes products for human and veterinary use, pharmaceutical ingredients and biological fertilizers. Additionally, the Company is engaged in the research and development activities.
Sector
Pharmaceuticals
Calendar
23/09/2024 - Ex-dividend day for final dividend
More about the company

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+38.51% 73TCr
NOVO NORDISK A/S Stock Novo Nordisk A/S
+33.05% 60TCr
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.23% 35TCr
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.78% 33TCr
ABBVIE INC. Stock AbbVie Inc.
+1.35% 28TCr
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.00% 24TCr
NOVARTIS AG Stock Novartis AG
+8.09% 20TCr
ROCHE HOLDING AG Stock Roche Holding AG
-5.77% 20TCr
AMGEN INC. Stock Amgen Inc.
+6.19% 16TCr
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. ATB Stock
  4. Stock